| Investment Objective | |
| The investment objective of the Scheme is to generate returns corresponding to the total returns of the securities as represented by the CRISIL IBX Gilt Index – April 2033 before expenses, subject to tracking errors. The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved. | |
| Fund Category: Index Funds (Debt) | |
| Fund Snapshot | |
| Date of Allotment : Dec 22, 2023 | |
| Benchmark: CRISIL IBX Gilt Index – April 2033 | |
| Fund Manager - Mr. Bhupesh Bameta Managing the Fund Since: December 22, 2023 Experience in Managing the Fund: 2.4 Years |
|
| Fund Manager - Mr. Sanjay Godambe Managing the Fund Since: December 22, 2023 Experience in Managing the Fund: 2.4 Years |
|
| Load Structure (as % of NAV) (Incl. for SIP) | |
| Entry Load: | NIL |
| Exit Load: | NIL |
| AUM as on April 30, 2026 (in ₹Crore) | |
| Monthly Average AUM | 34.11 |
| AUM as on last day | 33.98 |
| Base Expense Ratio (BER) | |
| Regular | 0.39% |
| Direct | 0.18% |
| BER excludes brokerage incurred towards execution of trades, transaction cost & statutory levies as applicable to investors. | |
| NAV as on April 30, 2026 | |
| NAV Regular | 11.80 |
| NAV Direct | 11.86 |
| Tracking Error | |
| Tracking Error Regular | 1.03% |
| Tracking Error Direct | 1.03% |
![]() |
|
| Sectoral Contribution(in %) |
![]() |
| Portfolio Holdings |
![]() |
| Debt Quants | |
| Modified Duration | 5.05 years |
| Average Maturity | 6.58 years |
| Yield to Maturity | 7.06% |
| Macaulay Duration | 5.23 years |
| Debt & Debt Related | Rating |
% to Net Assets |
| Debt & Debt Related | ||
| Government Bond | 95.48% | |
| 7.26% GOVERNMENT OF INDIA 06FEB33 | SOV | 95.48% |
| Net Cash and Cash Equivalent | 4.52% | |
| Grand Total | 100.00% |
|
| Scheme Name | |
Aditya Birla Sun Life CRISIL IBX Gilt April 2033 Index Fund |
|
| This product is suitable for investors who are seeking*: | |
|
|
Risk-o-meter ![]() |
Benchmark Risk-o-meter CRISIL IBX Gilt Index – April 2033 ![]() |
| *Investors should consult their financial advisors if in doubt whether the product is suitable for them. | |